scientific programme of int'l liver meeting online

[stef2011]

http://www1.easl.eu/easl2011/program/Posters/

[StephenCastlecrag]

Just to reinforce about your concerns with safety when trying to rejuvenate "exhausted" immune response [caused by inhibitory pathways], a new article in Nature Medicine warns about the risk:

"Reconstitution of T cell immunity is particularly relevant to chronic hepatitis B, where a
"sustained cure by direct-acting antivirals is uncommon. HBV genomes are not easily eliminated from the liver, and so immune control must be sustained for a lifetime. Pegylated type I interferon is thought to provide a durable cure after discontinuation of therapy by modulating immunity."
"The number of inhibitory pathways that must be blocked to overcome T cell exhaustion may be reduced by combination with other approaches, such as therapeutic vaccination15 and/or direct-acting antivirals or type I interferon. As there is no clinical precedent for combining immunomodulatory antibodies or adding therapeutic antiviral vaccines to the regimen, well-designed preclinical studies for HBV and HCV infection will be crucial to minimize risk."

But just to cheer you up a bit. IL-7:

"The observation that IL-7 is able to potently enhance unspecific and specific immune responses, and at the same time prevent immunopathological damage, is fascinating and astounding." [due to IL-22 mediated protection]

But anyhow, all this is very early days and the risk you mention are always there:

"Unfortunately, one major caveat for immediate translation to the clinic is the finding that IL-7 treatment also potently promotes the development of autoreactive T cells"

[stef2011]

yes nothing at all, same thing in boston, it looks like a cirus to sell products now they poitnt o make money on the new hcv drugs until 2017 when they no longer get money from etv and tnf

i do appreciate there are nucs tosave our lives from hbv and hcv but i don t like that cirus made online for selling which has nothing to do with curing diseases

luckily we have alinia thanks to the fact it was already marketed around the wrold by many and.....
i got a response from GcMAF producers

I have heard a few physicians say that it is worth a try for Hep. in particular. We do not know if they have tried it yet.
The product works independently. It does not target a specific pathogen, it enhances the immune system, which then can take care of pathogens itself.

if the liver is healthy and has no fibrosis or mild fibrosis like f1 or f2 i d try it immediately, the only issues are if there is a lot of hbvdna immune system will make acute hbv to clear it, it means an alt flare that can reach 1000 easily, that's why liver must be ok and not cirrotic

with hbvdna und the alt flare should not happen because there is just an increase of hbsab which makes hbsag negative

[StephenCastlecrag]

I did a quick check of the programs, it seems there is no new news on Myrcludex B, except a paper on animal studies by the same Lab in Heidelberg. Nothing on REP 9AC either. I assume there is nothing on Alinia? Also there is nothing on IL-7?

[stef2011]

ASSOCIATION OF HBSAG DECLINE WITH INNATE AND ADAPTIVE IMMUNE RESPONSES

Conclusion: i) HBV-specific CD8(+) T-cell immune responses in acute hepatitis B appear only when HBsAg levels decline, ii) the assessment of immune responses confirms suggested clinically HBsAg thresholds of sustained control of HBV-replication and iii) HBsAg levels show an association with activation of both, adaptive and innate immunity during acute hepatitis HBV-infection.